CPT® Code 81213

Deleted

Molecular genetic testing, specifically CPT® Code 81213, is utilized to identify uncommon duplication and deletion variants in the BRCA1 and BRCA2 genes. These genes, located on chromosome 17 and chromosome 13 respectively, are critical tumor suppressors that play a vital role in maintaining the stability of genetic material and preventing the uncontrolled proliferation of cells. Mutations in these genes are associated with a hereditary increased risk of developing breast cancer and other types of cancers in both men and women. For instance, mutations in the BRCA1 gene in women are linked to a heightened risk of early-onset breast cancer, as well as an increased likelihood of cervical, ovarian, uterine, pancreatic, and colon cancers. In men, BRCA1 mutations elevate the risk of breast cancer and, to a lesser extent, pancreatic and testicular cancers. Similarly, BRCA2 mutations in women are associated with a higher risk of pancreatic, stomach, gallbladder, bile duct cancers, and melanoma, while men with BRCA2 mutations face increased risks for breast, pancreatic, and prostate cancers. The testing process involves a comprehensive analysis of the BRCA1 and BRCA2 genes to detect specific mutations, including those that may be classified as variants of uncertain significance (VUS). These VUS may include missense mutations or potential splice site alterations that are often more prevalent in certain ethnic or minority populations. It is noteworthy that approximately half of the uncommon mutations identified in the BRCA1 and BRCA2 genes lack established clinical significance, underscoring the complexity of genetic testing in this area. The identification of these variants is crucial for assessing cancer risk and guiding clinical decision-making for individuals who may carry these mutations.